about
Utility of adiponectin as a biomarker predictive of glycemic efficacy is demonstrated by collaborative pooling of data from clinical trials conducted by multiple sponsors.New frontiers in the treatment of diabetic dyslipidemiaConcomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetesThe PPAR-gamma agonist, darglitazone, restores acute inflammatory responses to cerebral hypoxia-ischemia in the diabetic ob/ob mouse.Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases.Methylsulfonylnitrobenzoates, a new class of irreversible inhibitors of the interaction of the thyroid hormone receptor and its obligate coactivators that functionally antagonizes thyroid hormone.Protection of neurons and microglia against ethanol in a mouse model of fetal alcohol spectrum disorders by peroxisome proliferator-activated receptor-γ agonists.Therapeutic effects of troglitazone in experimental chronic pancreatitis in miceVernonia amygdalina simultaneously suppresses gluconeogenesis and potentiates glucose oxidation via the pentose phosphate pathway in streptozotocin-induced diabetic ratsLong-term glycaemic control with pioglitazone in patients with type 2 diabetes.Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat.Rosiglitazone decreases postprandial production of acylation stimulating protein in type 2 diabetics.Unbuckling lipodystrophy from insulin resistance and hypertension.Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.PPARγ activation prevents impairments in spatial memory and neurogenesis following transient illnessComparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with MetforminA randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol.Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia.Postprandial hyperglycemia as an etiological factor in vascular failureEvaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT.Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients.Effect of systemic medications on onset and progression of diabetic retinopathy.New lipid-lowering drugs: an update.Pleiotropic role of PPARγ in intracerebral hemorrhage: an intricate system involving Nrf2, RXR, and NF-κB.Development of improved PPARβ/δ inhibitors.Systemic hyperthermia masks the neuroprotective effects of MK-801, but not rosiglitazone in brain ischaemia.A futile metabolic cycle activated in adipocytes by antidiabetic agents.PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic ApproachesThe PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly.Rosiglitazone, but not pioglitazone, improves myocardial systolic function in type 2 diabetic patients: a tissue Doppler study.Insulin resistance due to lipid-induced signaling defects could be prevented by mahanine.Preadipocyte number in omental and subcutaneous adipose tissue of obese individuals.Beneficial effects of troglitazone on neutrophil dysfunction in multiple low-dose streptozotocin-induced diabetic mice.Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study.Intervening on HDL-C: is it possible? Does it work?Combination therapy of rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, and NMDA receptor antagonist (MK-801) on experimental embolic stroke in rats.Activation of peroxisome proliferator-activated receptor-alpha and -gamma in auricular tissue from heart failure patients.Coffee and Type 2 Diabetes Risk
P2860
Q33474320-2A46A662-84CF-4AA9-A6BF-354DE39828B7Q33776236-BFDD46BE-5C1A-4066-9AFD-0265CCC99396Q33797616-1E89CED6-9642-4D91-8A28-C2BDF3CB2138Q34170824-CDA043B8-259E-45E2-9A1F-8F9352485432Q34406470-1E754175-173F-41EE-82EE-99E6D69BC0DAQ34751984-F4A2FB25-2326-4523-AB31-7B0E38F27BC8Q35015002-779B6DB2-3C52-4395-9E1B-1CAF8E463DBAQ35083721-D508AAB6-38F9-4216-B07C-B7016634EED8Q35379260-DC5A5298-5948-46DC-A906-2E076F18BC54Q35728336-31B7CCF8-C2D5-4DA3-B043-D694C2CCD31AQ35745608-9A02E6FE-1C78-4E58-9207-575790662B23Q35808559-809E74AF-ABD5-4E06-B750-DCD1FD473C6DQ35835637-65818EAA-26D8-4C0A-99C1-CC19EE2623CCQ35941128-02FFB80B-F3E4-46C1-93DA-30B4D3033BCDQ36605328-06B875C3-AD4D-4EE4-9B81-9FF8C32E75A0Q37056847-E24DE32A-65B1-49EF-9AEF-256F894AF02DQ37098328-7452E288-B8BD-4728-B1F3-A808E24389F9Q37335663-6FBAA1B4-4B44-41FE-8943-FC8B2B338C33Q37464262-10112469-4123-43F2-A1E1-C5C62BF16E91Q37547069-01B3DE93-2683-4635-AA3E-F0FC0310EFD6Q37600230-C7B3F39B-3598-4064-910F-9CBD87BB020FQ37776148-E3A0B35A-FA69-4808-AF4C-28FD421E5874Q37984782-82703EF9-909F-45A7-83F8-526CBAB26777Q38272127-6C0AE604-A3C6-4775-A987-761FD917D11DQ39453236-035B209B-C7AE-447C-AA29-1E560AD73283Q40360847-8B1ED6D6-FD2F-419F-BB3D-EEF424A63ED9Q40700524-96FC30F9-69A1-4088-9D76-5E113A62CD7FQ41938308-74535F59-FC59-417F-A5DC-CE8FF92E0132Q42516933-674ECEC5-A70D-4A66-AACC-EAFD4468C8A6Q43088982-B40121E1-6A7B-42EA-B069-6D7B5DEEF903Q43261971-8CEA9813-85BE-4567-976F-A78F44A1708EQ44814841-A8B59445-F943-4723-B346-155F99490ABCQ44990872-1E974EE2-21AC-4EE2-9877-91156C720A69Q46885175-D4E92BDA-E2FA-4139-8631-7E3E3A44334DQ46951878-47BF3D7A-A6BA-4307-9385-74C6242568ADQ46970970-2EEE9F19-53F5-4394-95CD-320041B41644Q54640549-77E206A0-4EAB-463D-8CA5-8AFC01955B76Q59136514-873363B7-18F9-44A5-A53D-7B9E91033795
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Glitazones: clinical effects and molecular mechanisms.
@ast
Glitazones: clinical effects and molecular mechanisms.
@en
Glitazones: clinical effects and molecular mechanisms.
@nl
type
label
Glitazones: clinical effects and molecular mechanisms.
@ast
Glitazones: clinical effects and molecular mechanisms.
@en
Glitazones: clinical effects and molecular mechanisms.
@nl
prefLabel
Glitazones: clinical effects and molecular mechanisms.
@ast
Glitazones: clinical effects and molecular mechanisms.
@en
Glitazones: clinical effects and molecular mechanisms.
@nl
P356
P1433
P1476
Glitazones: clinical effects and molecular mechanisms.
@en
P304
P356
10.1080/713782132
P407
P577
2002-01-01T00:00:00Z